689258-74-0

Basic information

• Product Name: (E)-tert-butyl((4-(4-methoxyphenyl)but-3-en-1-yl)oxy)dimethylsilane
• Synonyms: (E)-tert-butyl((4-(4-methoxyphenyl)but-3-en-1-yl)oxy)dimethylsilane
• CAS NO: 689258-74-0
• Molecular Weight: 292.494
• Mol File: 689258-74-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (E)-tert-butyl((4-(4-methoxyphenyl)but-3-en-1-yl)oxy)dimethylsilane(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-tert-butyl((4-(4-methoxyphenyl)but-3-en-1-yl)oxy)dimethylsilane(689258-74-0)
• EPA Substance Registry System: (E)-tert-butyl((4-(4-methoxyphenyl)but-3-en-1-yl)oxy)dimethylsilane(689258-74-0)

Safety Data

• Hazardous Substances Data: 689258-74-0(Hazardous Substances Data)

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 89031-84-5 3-(tert-butyldimethylsilyloxy)propyl bromide 
• 120379-76-2 [3-[(tert-butyldimethylsilyl)oxy]propyl]triphenylphosphonium bromide 
• 123-11-5 4-methoxy-benzaldehyde 
• 92587-78-5 trans-4-(p-methoxyphenyl)-3-buten-1-ol 
• 127404-73-3 (3E)-4-(4-methoxyphenyl)but-3-enoic acid 

Downstream Products

• 1236889-47-6 (E)-1-methoxy-4-(3-phenylbut-1-en-1-yl)benzene 
• 150660-28-9 (E)-1-methoxy-4-(4-phenylbut-1-en-1-yl)benzene 

Relevant articles and documents

Palladium-catalyzed allylic cross-coupling reactions of primary and secondary homoallylic electrophiles

The Pd(0)-catalyzed allylic cross-coupling of homoallylic tosylate substrates using boronic acids and pinacol esters is reported. The reaction uses 2-(4,5-dihydro-2-oxazolyl)quinoline (quinox) as a ligand and is performed at ambient temperature. The scope of the reaction is broad in terms of both the boronate transmetalating reagent and the substrate and includes secondary tosylates. Mechanistic studies support an alkene-mediated SN2-type stereoinvertive oxidative addition of unactivated primary and secondary alkyl tosylates.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.